drugset / Trial / NCT05272826
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate efficacy and tolerability of iberdomide, bortezomib, dexamethasone and isatuximab on demand administered in combination for newly diagnosed transplant-ineligible multiple myeloma patients.
Timeline
- Start
- 2024-12-12
- Primary completion
- 2028-03
- Completion
- 2031-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | — | Subcutaneous |
| Subject | Dexamethasone | Small molecule | — | Oral |
| Subject | Iberdomide | Small molecule | — | Oral |
| Subject | Isatuximab | Monoclonal antibody | — | Subcutaneous |